Qualitative analysis identifies barriers and promoters to research translation in hereditary angioedema treatment, indicating improvements needed for patient care.
Key Points
The main barrier to clinical care in hereditary angioedema is perceived prior authorization for medications, limiting evidence-based treatment options.
Interviews highlighted other barriers like laboratory testing difficulties and deficits in both clinician and patient understanding of hereditary angioedema.
Promoters for research translation included medication availability and shared decision-making with patients, enhancing their engagement in care.
The study underscores the need for better understanding and resources to improve quality of life in patients with hereditary angioedema.